19
Agilent NGS Innovations for Cancer Research Tim Wise Genomics Product Specialist Diagnostics and Genomics Group PR7000-0837

Agilent NGS Innovations for Cancer Research...Fight Cancer Molecular Dx is revolutionizing cancer treatment Number of actionable mutations in lung cancer is constantly increasing •

  • Upload
    others

  • View
    4

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Agilent NGS Innovations for Cancer Research...Fight Cancer Molecular Dx is revolutionizing cancer treatment Number of actionable mutations in lung cancer is constantly increasing •

Agilent NGS Innovations for Cancer Research

Tim Wise

Genomics Product Specialist

Diagnostics and Genomics Group

PR7000-0837

Page 2: Agilent NGS Innovations for Cancer Research...Fight Cancer Molecular Dx is revolutionizing cancer treatment Number of actionable mutations in lung cancer is constantly increasing •

Agilent acquires Cartagenia enabling

clinical analysis of genomic data

2005 2009 2012 2000

Agilent ships first

DNA microarrays

Agilent acquires Dako, leader in cancer

diagnostics

Diagnostic and Genomics Group formed to

lead Agilent’s entry into clinical sciences

2015

Array-based comparative genomic

hybridization introduced

Agilent begins transformation into

a life sciences company

NGS enters new era with Agilent’s

selective sequencing technology

SureSelect

Agilent Technologies Delivering innovations that advance human health

ISH product portfolio enables

higher resolution ISH

2016

Agilent announces investment in

Lasergen to move NGS

technology forward

2017

Agilent acquires Multiplicom to expand

clinical genomics workflow solutions

Agilent acquires Halo Genomics to grow

sequencing technology portfolio

2011

PR7000-0837

Page 3: Agilent NGS Innovations for Cancer Research...Fight Cancer Molecular Dx is revolutionizing cancer treatment Number of actionable mutations in lung cancer is constantly increasing •

Precision Medicine and

Personalized Therapy

Agilent in the Fight Against Cancer Agilent expertise spans the entire spectrum of technologies

FFPE Sample

Handling

Molecular

Assays

• True leader in

target enrichment

• Fast and easy customization of molecular assays to fit your needs

• History of translational

success with arrays

• A growing menu of FISH and CISH probes for FFPE samples

• FFPE-compatible target enrichment platform and QC assays

• Unmatched CDx development expertise

• Trusted partnerships with major pharmaceutical companies

Tissue-based

Diagnostics

• Integrated automation for tissue-based staining

• Continuous and flexible loading of IHC and ISH assays

• Rich portfolio of antibodies and ISH probes

Companion

Diagnostics

Next

Generation

Sequencing

Data Analysis

Pipelines

Companion

diagnostics

FFPE to

Molecular

Assays

Staining

solutions

Molecular

Assay

Expertise

Genomics and Molecular

Analysis Routine Diagnostics

For Research Use Only.

Not for use in diagnostic procedures.

PR7000-0837

Page 4: Agilent NGS Innovations for Cancer Research...Fight Cancer Molecular Dx is revolutionizing cancer treatment Number of actionable mutations in lung cancer is constantly increasing •

Fight Cancer Molecular Dx is revolutionizing cancer treatment

Number of actionable mutations

in lung cancer is constantly

increasing

• MDx(1) techniques have significantly

increased the understanding of the

underlying driver mutations

• An increasing number of these

mutations have become actionable with

new drugs (e.g. Iressa, Xalkori and

Tarceva)

• By using NGS and FISH together,

almost all of the currently actionable

mutations in lung cancer can be

identified

(1) Molecular Diagnostic

Few actionable mutations

by PCR & Sanger

2000

Many actionable mutations

by NGS & FISH

2014

PR7000-0837

For Research Use Only.

Not for use in diagnostic procedures.

Page 5: Agilent NGS Innovations for Cancer Research...Fight Cancer Molecular Dx is revolutionizing cancer treatment Number of actionable mutations in lung cancer is constantly increasing •

Agilent NGS products by workflow

Automation

Library Prep /

target enrichment QC Sequencing Analysis

Interpretation /

Reporting

PR7000-0837

For Research Use Only.

Not for use in diagnostic procedures.

Page 6: Agilent NGS Innovations for Cancer Research...Fight Cancer Molecular Dx is revolutionizing cancer treatment Number of actionable mutations in lung cancer is constantly increasing •

DNA Targeted-Seq: SureSelect + HaloPlex

Methylation Targeted-Seq:

SureSelect RNA Targeted-Seq:

SureSelect

Whole genome sequencing:

SureSelect QXT

Transcriptome sequencing:

SureSelect strand-specific

A Broad NGS Portfolio to Advance Constitutional and Cancer Research

SureDesign

SureCall

Cartagenia Bench Consortium

PR7000-0837

For Research Use Only.

Not for use in diagnostic procedures.

Page 7: Agilent NGS Innovations for Cancer Research...Fight Cancer Molecular Dx is revolutionizing cancer treatment Number of actionable mutations in lung cancer is constantly increasing •

Target Enrichment: Focus on what Matters

Key Goals of Target Enrichment

• Focus on a subset of the genome

• Achieve greater depth in targeted regions

- Discover more mutations, SNPs and Indels

• Lower sequencing costs and obtain faster time to result

gDNA

Enriched Targets

SureSelect HaloPlex

PR7000-0837

For Research Use Only.

Not for use in diagnostic procedures.

Page 8: Agilent NGS Innovations for Cancer Research...Fight Cancer Molecular Dx is revolutionizing cancer treatment Number of actionable mutations in lung cancer is constantly increasing •

Two target enrichment platforms

Automation

Library Prep /

target enrichment QC Sequencing Analysis

Interpretation /

Reporting

• Hybridization-based enrichment (1.5 days)

• Most published, gold standard platform

• Uniform enrichment for large and/or custom panels

• Molecular Barcodes with HS-XT coming in May

• Advanced amplicon-based enrichment (<1 day)

• Ideal balance of workflow and performance

• <1% allele frequency detection with molecular

barcodes

Molecular

barcode

Tailoring and updating gene panel content

- Minimal optimization

- Catalog quality

PR7000-0837

For Research Use Only.

Not for use in diagnostic procedures.

Page 9: Agilent NGS Innovations for Cancer Research...Fight Cancer Molecular Dx is revolutionizing cancer treatment Number of actionable mutations in lung cancer is constantly increasing •

PR7000-0837

For Research Use Only.

Not for use in diagnostic procedures.

Page 10: Agilent NGS Innovations for Cancer Research...Fight Cancer Molecular Dx is revolutionizing cancer treatment Number of actionable mutations in lung cancer is constantly increasing •

SureSelect ClearSeq Cancer Research Panels

COMPREHENSIVE

FOCUSED

Fully customizable! Power up a catalog product with additional content, or

design using your own targets.

ClearSeq

AML

ClearSeq

Cancer

(Hotspots)

Flexibility

Kinome

OR

ClearSeq Comprehensive Cancer targets 151 genes

New in May

HS-XT with

Molecular Barcodes

Higher Sensitivity

for minor allele

frequency detection

below 1%

PR7000-0837

For Research Use Only.

Not for use in diagnostic procedures.

Page 11: Agilent NGS Innovations for Cancer Research...Fight Cancer Molecular Dx is revolutionizing cancer treatment Number of actionable mutations in lung cancer is constantly increasing •

High-output Desktop

RESEARCH AND

TRANSLATIONAL CLINICAL RESEARCH

SureSelect

Human All Exon V6

OneSeq Constitutional

Research Panel

SureSelect

Clinical Research Exome v2

SureSelect

Focused Exome

ClearSeq

Inherited Disease

Capture Size

and # Genes

58Mb

whole exome

28Mb

genomewide backbone +

disease-focused mutation

panel

66Mb

whole exome

16Mb

~5700 genes

10.5Mb

~2800 genes

Key Features

Best uniformity

Best exome-wide

breadth and depth of

coverage

Copy number and LOH in

addition to SNPs and Indels

Increased depth in

disease-associated regions

Includes intronic disease-

associated regions

Desktop exome

Targets ONLY disease-

associated targets

ONLY targets genes

known to cause

inherited disorders

Agilent SureSelect Exomes A range of options for the flexibility you need

PR7000-0837

For Research Use Only.

Not for use in diagnostic procedures.

Page 12: Agilent NGS Innovations for Cancer Research...Fight Cancer Molecular Dx is revolutionizing cancer treatment Number of actionable mutations in lung cancer is constantly increasing •

SureSelect Human All Exon V6 Bridging the gap

Coverage gaps in exome sequencing

Most comprehensive content

All Exon V6 + COSMIC

All Exon V6 + UTR

All Exon V6 + Custom

PR7000-0837

For Research Use Only.

Not for use in diagnostic procedures.

Page 13: Agilent NGS Innovations for Cancer Research...Fight Cancer Molecular Dx is revolutionizing cancer treatment Number of actionable mutations in lung cancer is constantly increasing •

SureSelectXT HS

Coming Soon!

What is it?

• Agilent’s highest sensitivity hybrid capture-based library prep and target

enrichment solution for NGS

What does it do?

• 10 ng input

• Optimized for high-quality intact DNA, low- and high-quality FFPE DNA

• Molecular barcode (MBC) tagged libraries increase positive predictive value (PPV)

• Higher complexity libraries with higher percentage reads in targeted regions

• 90 minute hybridization and master-mixed reagents for faster, more efficient workflow

PR7000-0837

For Research Use Only.

Not for use in diagnostic procedures.

Page 14: Agilent NGS Innovations for Cancer Research...Fight Cancer Molecular Dx is revolutionizing cancer treatment Number of actionable mutations in lung cancer is constantly increasing •

SureSelect XT RNA Enrichment:

Using All Exon

V6 + UTR

FFPE Direct to Capture

PR7000-0837

For Research Use Only.

Not for use in diagnostic procedures.

Page 15: Agilent NGS Innovations for Cancer Research...Fight Cancer Molecular Dx is revolutionizing cancer treatment Number of actionable mutations in lung cancer is constantly increasing •

SureSelect XT RNA Enrichment:

Strand Specific

PR7000-0837

For Research Use Only.

Not for use in diagnostic procedures.

Page 16: Agilent NGS Innovations for Cancer Research...Fight Cancer Molecular Dx is revolutionizing cancer treatment Number of actionable mutations in lung cancer is constantly increasing •

Sample prep QC

Automation

Library Prep /

target enrichment QC Sequencing Analysis

Interpretation /

Reporting

Sample prep QC: save operational cost & ensure data quality

2100 Bioanalyzer: widely accepted QC standard

• Up to 12 samples, manual

4200 tapestation: New release

• 96 sample walkaway operation

• Scalable throughput at a constant cost

• Ready-to-use consumables

NGS FFPE QC kit

• Qualify and quantify amplifiable

DNA in challenging samples

• Help optimize library prep workflow

PR7000-0837

For Research Use Only.

Not for use in diagnostic procedures.

Page 17: Agilent NGS Innovations for Cancer Research...Fight Cancer Molecular Dx is revolutionizing cancer treatment Number of actionable mutations in lung cancer is constantly increasing •

Analysis, interpretation and reporting

Automation

Library Prep /

target enrichment QC Sequencing Analysis

Interpretation /

Reporting

Cartagenia bench lab for molecular pathology

• Variant assessment and reporting

• Key features

• fast turnaround time

• Molecular profile in tumor-type context

• Clinical grade reports

SureCall: Make NGS analysis easy, fast, and accurate

• Alignment and variant calling

• Simple 3-step workflow

• Fast time-to-results

Analysis Reporting

For Research Use Only. Not for use in diagnostic procedures marketed in the USA as exempt Class I Medical Device and in Europe and Canada as a Class I Medical Device

PR7000-0837

Page 18: Agilent NGS Innovations for Cancer Research...Fight Cancer Molecular Dx is revolutionizing cancer treatment Number of actionable mutations in lung cancer is constantly increasing •

Sequencer

Automation

Library Prep /

target enrichment QC Sequencing Analysis

Interpretation /

Reporting

• Houston, Texas based

• Proprietary “lightning terminators”

sequencing chemistry

• $80M investment in Lasergen (48% stake)

• To provide end-to-end NGS workflow

solution

PR7000-0837

For Research Use Only.

Not for use in diagnostic procedures.

Page 19: Agilent NGS Innovations for Cancer Research...Fight Cancer Molecular Dx is revolutionizing cancer treatment Number of actionable mutations in lung cancer is constantly increasing •

Agilent NGS for pathology

Automation

Library Prep /

target enrichment QC Sequencing Analysis

Interpretation /

Reporting

Questions?

For customers in a clinical

environment, ask your

Agilent / Cartagenia

representative for more

information about our new

Alissa interpretation &

reporting solution.

PR7000-0837

For Research Use Only.

Not for use in diagnostic procedures.